Skip to main content
SpringerLink
Log in

Cisplatin/etoposide

Death: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Funt S, et al. Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). Journal of Clinical Oncology 36 (Suppl. 1): abstr. 4550, No. 15, 20 May 2018. Available from: URL: http://doi.org/10.1200/JCO.2018.36.15_suppl.4550 [abstract] - USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cisplatin/etoposide. Reactions Weekly 1744, 87 (2019). https://doi.org/10.1007/s40278-019-58986-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-58986-9

Search

Navigation